Change in high-density lipoprotein cholesterol and risk of subsequent hospitalization for coronary artery disease or stroke among patients with type 2 diabetes mellitus

American Journal of Cardiology

Volumn 108, Issue 8, 2011, Pages 1124-1128

  Nichols, Gregory A ^a   Vupputuri, Suma ^b   Rosales, A Gabriela ^a  

^a Kaiser Permanente Center for Health Research   (Portugal)

^b CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DEMOGRAPHY; DRUG USE; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; STROKE; TRIACYLGLYCEROL BLOOD LEVEL;

CHOLESTEROL, HDL; CONFIDENCE INTERVALS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MORBIDITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; UNITED STATES;

EID: 80053939782     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2011.05.047     Document Type: Article

References (22)

1. C.S. Fox, M.J. Pencian, P.W.F. Wilson, N.P. Paynter, R.S. Vasan, R.B. D'Agostino, and Sen Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham Heart Study Diabetes Care 31 2008 1582 1584
2. J.J.P. Kastelein, W.A. van der Steeg, I. Holme, M. Gaffney, N.B. Cater, P. Barter, P. Deedwania, A.G. Olsson, M. Boekholdt, D.A. Demicco, M. Szarek, J.C. LaRosa, T.R. Pedersen, S.M. Grundy TNT Study Group, IDEAL Study Group, for the TNT and IDEAL Study Groups Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment Circulation 117 2008 3002 3009
3. Action to Control Cardiovascular Risk in Diabetes Study Group H.C. Gerstein, M.E. Miller, R.P. Byington, D.C. Goff, J.T. Bigger, J.B. Buse, W.C. Cushman, S. Genuth, F. Ismail-Beigi, R.H. Grimm, J.L. Probstfield, D.G. Simons-Morton, and W.T. Friedewald Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559 (Pubitemid 351831356)
4. The ADVANCE Collaborative Group A. Patel, S. MacMahon, J. Chalmers, B. Neal, L. Billot, M. Woodward, M. Marre, M. Cooper, P. Glasziou, D. Grobbee, P. Hamet, S. Harrap, S. Heller, L. Liu, G. Mancia, C.E. Mogensen, C. Pan, N. Poulter, A. Rodgers, B. Williams, S. Bompoint, B.E. de Galan, R. Joshi, and F. Travert Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572 (Pubitemid 351831357)
5. W. Duckworth, C. Abraira, T. Moritz, D. Reda, N. Emanuele, P.D. Reaven, F.J. Zieve, J. Marks, S.N. Davis, R. Hayward, S.R. Warren, S. Goldman, M. McCarren, M.E. Vitek, W.G. Henderson, G.D. Huang VADT Investigators Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 2009 129 139
6. American Diabetes Association Standards of medical care in diabetes2011 Diabetes Care 34 suppl 1 2011 S11 S61
7. W.E. Boden High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial Am J Cardiol 86 2000 19L 22L
8. R.W. Grant, and J.B. Meigs Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction Diabetes Care 30 2007 479 484 (Pubitemid 46354321)
9. S.R. Preis, M.J. Pencina, S.J. Hwang, R.B. D'Agostino Sr, P.J. Savage, D. Levy, and C.S. Fox Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study Circulation 120 2009 212 220
10. S.R. Preis, S.J. Hwang, S. Coady, M.J. Pencina, R.B. D'Agostino Sr, P.J. Savage, D. Levy, and C.S. Fox Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005 Circulation 119 2009 1728 1735
11. D.J. Gordon, J.L. Probstfield, R.J. Garrison, J.D. Neaton, W.P. Castelli, J.D. Knoke, D.R. Jacobs Jr, S. Bangdiwala, and H.A. Tyroler High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies Circulation 79 1989 8 15 (Pubitemid 19043669)
12. S.A. Grover, M. Kaouache, L. Joseph, P. Barter, and J. Davignon Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels Arch Intern Med 169 2009 1775 1780
13. V. Manninen, M.O. Elo, M.H. Frick, K. Haapa, O.P. Heinonen, P. Heinsalmi, P. Helo, J.K. Huttunen, P. Kaitaniemi, P. Koskinen, H. Menp, M. Mlkönen, M. Mnttri, S. Norola, A. Pasternack, J. Pikkarainen, M. Romo, T. Sjöblom, and E.A. Nikkil Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study JAMA 260 1988 641 651
14. B.G. Brown, X.Q. Zhao, A. Chait, L.D. Fisher, M.C. Cheung, J.S. Morse, A.A. Dowdy, E.K. Marino, E.L. El Bolson, P. Alaupovic, J. Frohlich, and J.J. Albers Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592 (Pubitemid 33126837)
15. T.R. Pederson, A.G. Olsson, O. Faergeman, J. Kjekshus, H. Wedel, K. Berg, L. Wilhelmsen, T. Haghfelt, G. Thorgeirsson, K. Pyörl, T. Miettinen, B. Christophersen, J.A. Tobert, T.A. Musliner, and T.J. Cook Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) Circulation 97 1998 1453 1460 (Pubitemid 28191300)
16. S.J. Robins, D. Collins, J.T. Wittes, P.D. Papademetriou, P.C. Deedwania, J.R. Schaefer, R. McNamara, M.L. Kashyap, J.M. Hershman, L.F. Wexler, H.B. Rubins VA-HIT Study Group Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial JAMA 285 2001 1585 1591 (Pubitemid 32240250)
17. G.A. Nichols, B.M. Ambegaonkar, V. Sazonov, and J.B. Brown Frequency of obtaining National Cholesterol Education Program Adult Treatment Panel III goals for all major serum lipoproteins after initiation of lipid altering therapy Am J Cardiol 104 2009 1689 1694
18. S.M. Grundy, J.I. Cleeman, C.N. Bairey-Merz, H.B. Brewer Jr, L.T. Clark, D.B. Hunninghake, R.C. Pasternak, S.C. Smith, N.J. Stone Coordinating Committee of the National Cholesterol Education Program, American College of Cardiology Foundation, American Heart Association Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239 (Pubitemid 38924592)
19. M. Davidson, P.M. Meyer, S. Haffner, S. Feinstein, R. D'Agostino Sr, G.T. Kondos, A. Perez, Z. Chen, and T. Mazzone Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus Circulation 117 2008 2123 2130 (Pubitemid 351572171)
20. S.J. Nicholls, E.M. Tuzcu, K. Wolski, O. Bayturan, A. Lavoie, K. Uno, S. Kupfer, A. Perez, R. Nesto, and S.E. Nissen Lowering the triglyceride/high- density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) Study J Am Coll Cardiol 57 2011 153 159
21. H.N. Ginsberg, M.B. Elam, L.C. Lovato, J.R. Crouse III, L.A. Leiter, P. Linz, W.T. Friedewald, J.B. Buse, H.C. Gerstein, J. Probstfield, R.H. Grimm, F. Ismail-Beigi, J.T. Bigger, D.C. Goff Jr, W.C. Cushman, D.G. Simons-Morton, R.P. Byington, and R.P. Byington Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
22. A. Keech, R.J. Simes, P. Barter, J. Best, R. Scott, M.R. Taskinen, P. Forder, A. Pillai, T. Davis, P. Glasziou, P. Drury, Y.A. Kesniemi, D. Sullivan, D. Hunt, P. Colman, M. d'Emden, M. Whiting, C. Ehnholm, M. Laakso FIELD Study Investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861